These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 16400244)

  • 1. Beyond monoamines: glutamatergic function in mood disorders.
    Kugaya A; Sanacora G
    CNS Spectr; 2005 Oct; 10(10):808-19. PubMed ID: 16400244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders.
    Machado-Vieira R; Manji HK; Zarate CA
    Neuroscientist; 2009 Oct; 15(5):525-39. PubMed ID: 19471044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glutamatergic modulators: the future of treating mood disorders?
    Zarate C; Machado-Vieira R; Henter I; Ibrahim L; Diazgranados N; Salvadore G
    Harv Rev Psychiatry; 2010; 18(5):293-303. PubMed ID: 20825266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The role of the glutamatergic system in pathophysiology and pharmacotherapy for depression: preclinical and clinical data].
    Paslakis G; Gass P; Deuschle M
    Fortschr Neurol Psychiatr; 2011 Apr; 79(4):204-12. PubMed ID: 21117011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status.
    Henter ID; Park LT; Zarate CA
    CNS Drugs; 2021 May; 35(5):527-543. PubMed ID: 33904154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of glutamate on the action of antidepressants.
    Hashimoto K
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1558-68. PubMed ID: 20600468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glutamatergic approaches in major depressive disorder: focus on ketamine, memantine and riluzole.
    Owen RT
    Drugs Today (Barc); 2012 Jul; 48(7):469-78. PubMed ID: 22844658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole.
    Banasr M; Chowdhury GM; Terwilliger R; Newton SS; Duman RS; Behar KL; Sanacora G
    Mol Psychiatry; 2010 May; 15(5):501-11. PubMed ID: 18825147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Employing pharmacologic treatment of bipolar disorder to greatest effect.
    Schatzberg AF
    J Clin Psychiatry; 2004; 65 Suppl 15():15-20. PubMed ID: 15554791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression.
    Zarate CA; Quiroz JA; Singh JB; Denicoff KD; De Jesus G; Luckenbaugh DA; Charney DS; Manji HK
    Biol Psychiatry; 2005 Feb; 57(4):430-2. PubMed ID: 15705360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The anticonvulsant lamotrigine in treatment-resistant manic-depressive illness.
    Sporn J; Sachs G
    J Clin Psychopharmacol; 1997 Jun; 17(3):185-9. PubMed ID: 9169963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The current understanding of lamotrigine as a mood stabilizer.
    Hahn CG; Gyulai L; Baldassano CF; Lenox RH
    J Clin Psychiatry; 2004 Jun; 65(6):791-804. PubMed ID: 15291656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms.
    Sanacora G; Kendell SF; Levin Y; Simen AA; Fenton LR; Coric V; Krystal JH
    Biol Psychiatry; 2007 Mar; 61(6):822-5. PubMed ID: 17141740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments.
    Krystal JH; Sanacora G; Blumberg H; Anand A; Charney DS; Marek G; Epperson CN; Goddard A; Mason GF
    Mol Psychiatry; 2002; 7 Suppl 1():S71-80. PubMed ID: 11986998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of NMDA receptors in the pathophysiology and treatment of mood disorders.
    Ghasemi M; Phillips C; Trillo L; De Miguel Z; Das D; Salehi A
    Neurosci Biobehav Rev; 2014 Nov; 47():336-58. PubMed ID: 25218759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting glial physiology and glutamate cycling in the treatment of depression.
    Valentine GW; Sanacora G
    Biochem Pharmacol; 2009 Sep; 78(5):431-9. PubMed ID: 19376090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel glutamatergic drugs for the treatment of mood disorders.
    Lapidus KA; Soleimani L; Murrough JW
    Neuropsychiatr Dis Treat; 2013; 9():1101-12. PubMed ID: 23976856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder.
    Niciu MJ; Ionescu DF; Richards EM; Zarate CA
    J Neural Transm (Vienna); 2014 Aug; 121(8):907-24. PubMed ID: 24318540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel glutamatergic agents for major depressive disorder and bipolar disorder.
    Machado-Vieira R; Ibrahim L; Henter ID; Zarate CA
    Pharmacol Biochem Behav; 2012 Feb; 100(4):678-87. PubMed ID: 21971560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Riluzole in the treatment of mood and anxiety disorders.
    Pittenger C; Coric V; Banasr M; Bloch M; Krystal JH; Sanacora G
    CNS Drugs; 2008; 22(9):761-86. PubMed ID: 18698875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.